Trial Profile
Effect of natalizumab on cognitive function and cortical gray matter thickness in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 15 Jun 2015 New trial record
- 25 Apr 2015 Results (n=26) presented at the 67th Annual Meeting of the American Academy of Neurology.